NewAmsterdam Pharma (NAMS) Leases (2022 - 2025)
NewAmsterdam Pharma's Leases history spans 4 years, with the latest figure at $185000.0 for Q4 2025.
- For Q4 2025, Leases fell 57.08% year-over-year to $185000.0; the TTM value through Dec 2025 reached $185000.0, down 57.08%, while the annual FY2025 figure was $185000.0, 57.08% down from the prior year.
- Leases for Q4 2025 was $185000.0 at NewAmsterdam Pharma, down from $246000.0 in the prior quarter.
- Across five years, Leases topped out at $554000.0 in Q2 2024 and bottomed at $38000.0 in Q1 2024.
- The 4-year median for Leases is $277000.0 (2025), against an average of $279900.0.
- The largest YoY upside for Leases was 871.05% in 2025 against a maximum downside of 57.08% in 2025.
- A 4-year view of Leases shows it stood at $120000.0 in 2022, then crashed by 54.17% to $55000.0 in 2023, then soared by 683.64% to $431000.0 in 2024, then tumbled by 57.08% to $185000.0 in 2025.
- Per Business Quant, the three most recent readings for NAMS's Leases are $185000.0 (Q4 2025), $246000.0 (Q3 2025), and $308000.0 (Q2 2025).